What to Know About PBC, an Autoimmune Disease That Can Have No Symptoms
If the disease progresses to the point where you have liver failure, signs may be more obvious, like having a yellow tint to ...
Ipsen's IQIRVO Approval Has Intensified the Primary Biliary Cholangitis Market Space | DelveInsight
Primary biliary cholangitis (PBC), previously referred to as primary biliary cirrhosis, is a long-term liver condition ...
A beloved CT teacher suffers from end stage liver disease. How her family is trying to save her.
She understands God has a plan for her life,” her mother said, and is grateful for the “prayer warriors” who pray constantly ...
Hosted on MSN4d
Exploring the pathogenesis of autoimmune liver diseases from the heterogeneity of target cells
Autoimmune liver diseases (ALDs), including autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC), are complex conditions involving the liver's immune ...
pharmaphorum8d
Pruritus in PBC: Understanding its impact and the need for raising awareness
September is the perfect time to turn up the volume on conversations about Primary Biliary Cholangitis (PBC) and the symptoms ...
WebMD7d
A Close Look at Primary Biliary Cholangitis
Primary billiary cholangitis, or PBC, is a chronic disease that gradually damages the bile ducts, and eventually your liver. You may also hear it called primary billiary cirrhosis. Your bile ducts ...
Reuters21d
FDA advisers unconvinced by Intercept's liver disease drug benefits, safety
Intercept's Ocaliva received FDA's accelerated approval in 2016 to treat patients with primary biliary cholangitis, a rare disease that causes inflammation of small bile ducts in the liver and can ...
Reuters24d
US FDA staff questions confirmatory trial data for Intercept's liver disease drug
had been approved under the accelerated approval pathway to treat patients with primary biliary cholangitis (PBC), a rare disease that causes inflammation of small bile ducts in the liver and can ...
MedPage Today22d
Approved Liver Disease Drug Has No Clinical Benefit, FDA Panel Says
Safety was an issue for obeticholic acid because the main trial supporting its application (747-302, or COBALT) showed trends of excess liver transplants and death in people taking the drug ...
Ipsen’s Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary cholangitis in nearly a decade
European Commission grants conditional marketing authorization for Iqirvo® (elafibranor), first-in-class new treatment for primary biliary ...
COUR Pharmaceuticals Announces Positive Top-line Results from Phase 2a Study of CNP-104 in Primary Biliary Cholangitis
CNP-104 demonstrated potential efficacy across multiple immunological and clinical measurements, supporting its continued development as the first disease-modifying treatment for Primary Biliary ...